{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:04:04Z","timestamp":1780711444535,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00892-5","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:27:43Z","timestamp":1741951663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A new RP-HPLC approach for estimation of potential impurities of Fosamprenavir - method development and validation"],"prefix":"10.1186","volume":"26","author":[{"given":"Ramreddy","family":"Godela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-2502","authenticated-orcid":false,"given":"Vinod Kumar","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohana Vamsi","family":"Nuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan Kumar","family":"Jaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpi","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnaphanisri","family":"Ponnekanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punna Rao","family":"Suryadevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowri Sankararao","family":"Burle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinyas","family":"Mayasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavindra Kumar","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"892_CR1","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.2165\/00003495-200464180-00014","volume":"64","author":"TM Chapman","year":"2004","unstructured":"Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs. 2004;64:2101\u201324.","journal-title":"Drugs"},{"key":"892_CR2","unstructured":"Crowe SM, Katlama C, Murphy R. Fosamprenavir. Kucers\u2019 The Use of Antibiotics. CRC; 2017. pp. 4104\u201320."},{"key":"892_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1586\/14787210.5.3.349","volume":"5","author":"HA Torres","year":"2007","unstructured":"Torres HA, Arduino RC. Fosamprenavir calcium plus Ritonavir for HIV infection. Expert Rev Anti-infect Ther. 2007;5:349\u201363.","journal-title":"Expert Rev Anti-infect Ther"},{"issue":"2","key":"892_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2165\/00003088-200645020-00002","volume":"45","author":"MB Wire","year":"2006","unstructured":"Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137\u201368.","journal-title":"Clin Pharmacokinet"},{"key":"892_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/00003495-200565050-00005","volume":"65","author":"C Arvieux","year":"2005","unstructured":"Arvieux C. Amprenavir or Fosamprenavir plus Ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs. 2005;65:633\u201359.","journal-title":"Drugs"},{"key":"892_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/jac\/dkn525","volume":"63","author":"F Gatti","year":"2009","unstructured":"Gatti F, Nasta P, Loregian A, Puoti M, Matti A, Pagni S, Carosi G. Unboosted Fosamprenavir is associated with low drug exposure in HIV-infected patients with mild\u2013moderate liver impairment resulting from HCV-related cirrhosis. J Antimicrob Chemother. 2009;63:575\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"892_CR7","unstructured":"National Center for Biotechnology Information. (2024) PubChem compound summary for CID 131536. Fosamprenavir. Retrieved May 21, 2024."},{"key":"892_CR8","doi-asserted-by":"publisher","first-page":"e20181021","DOI":"10.1590\/0001-3765202020181021","volume":"92","author":"CF Cordeiro","year":"2020","unstructured":"Cordeiro CF, Bettio I, Trevisan MG. Studies on the characterization and polymorphic stability of Fosamprenavir. Acad Bras Cienc. 2020;92:e20181021.","journal-title":"Acad Bras Cienc"},{"issue":"10","key":"892_CR9","first-page":"3603","volume":"3","author":"SR Shah","year":"2012","unstructured":"Shah SR, Patel MA, Naik MV, Pradhan PK, Upadhyay UM. Recent approches of impurity profiling in pharmaceutical analysis: A review. Int J Pharm Sci Res. 2012;3(10):3603.","journal-title":"Int J Pharm Sci Res"},{"key":"892_CR10","first-page":"755","volume":"25","author":"S Gorog","year":"2006","unstructured":"Gorog S. The importance and the challenges of impurity profiling in modern pharmaceutical analysis. TrA C. 2006;25:755\u20137.","journal-title":"TrA C"},{"key":"892_CR11","unstructured":"Ingale SJ, Sahu CM, Paliwal RT, Vaidya S, Singhai AK. (2011) Advance approaches for the impurity profiling of pharmaceutical drugs: Int J Pharm Sci Res 2(7)."},{"key":"892_CR12","first-page":"877947","volume":"8","author":"SK Arora","year":"2014","unstructured":"Arora SK, Shabade SS, Kumar G, Ray PC, Singh GP. U S Patent No. 2014;8:877947.","journal-title":"U S Patent No"},{"key":"892_CR13","first-page":"712","volume":"11","author":"K Nekkala","year":"2019","unstructured":"Nekkala K, Kumar JS, Ramachandran D. Stability indicating RP-HPLC method for quantification of impurities in Fosamprenavir calcium drug substance. J Pharm Sci. 2019;11:712\u20137.","journal-title":"J Pharm Sci"},{"key":"892_CR14","first-page":"1049","volume":"2","author":"SS Pekamwar","year":"2015","unstructured":"Pekamwar SS, Bhavar GB, Aher KB, Kakad SJ. Validated UV spectrophotometric and HPTLC method for determination of Fosamprenavir calcium in pharmaceutical formulation. Austin J Anal Pharm Chem. 2015;2:1049\u201355.","journal-title":"Austin J Anal Pharm Chem"},{"key":"892_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/chromsci\/bmab109","volume":"60","author":"RC Rossi","year":"2022","unstructured":"Rossi RC, Moura JGL, Mossmann V, Weimer P, Fr\u00f6ehlich PE. A new, rapid and simple RP-HPLC method for stability quantification of a protease inhibitor in tablets. J Chromatogr Sci. 2022;60:671\u20137.","journal-title":"J Chromatogr Sci"},{"key":"892_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/chromsci\/bmt110","volume":"52","author":"M Chilukuri","year":"2014","unstructured":"Chilukuri M, Narayanareddy P, Hussianreddy K. Stability-indicating HPLC method for determination of Fosamprenavir calcium. J Chromatogr Sci. 2014;52:781\u20137.","journal-title":"J Chromatogr Sci"},{"key":"892_CR17","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.14233\/ajchem.2015.19007","volume":"27","author":"NM Rao","year":"2015","unstructured":"Rao NM, Gowrisankar D. Development and validation of stability indicating RP-HPLC method for Estimation of Fosamprenavir calcium in pure and pharmaceutical dosage forms. Asian J Chem. 2015;27:3484.","journal-title":"Asian J Chem"},{"key":"892_CR18","unstructured":"Anitha D, Manoranjani M, Parameswararao K. (2021) Affordable reverse phase fluid chromatographic strategy for the assessment of Fosamprenavir in tablets. Turk J Qual Inq 12(6)."},{"key":"892_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2174\/157488550904150525162237","volume":"9","author":"S Kurbanoglu","year":"2014","unstructured":"Kurbanoglu S, Ashrafi A, Vytras K, Uslu B, A Ozkan S. Determination and validation of the antiviral drugs using reverse phase high performance liquid chromatographic method. Curr Drug Ther. 2014;9:256\u201360.","journal-title":"Curr Drug Ther"},{"key":"892_CR20","first-page":"149","volume":"18","author":"MK Thimmaraju","year":"2019","unstructured":"Thimmaraju MK, Mondal P, Venu K, Babu GS, Rajkumar G, Padmaja B. Quantification of Fosamprenavir in spiked human plasma using liquid chromatography\u2013electrospray ionization\u2013tandem mass spectrophotometry\u2013application to Pharmacokinetic study. Egypt Pharm J. 2019;18:149\u201359.","journal-title":"Egypt Pharm J"},{"key":"892_CR21","doi-asserted-by":"publisher","first-page":"S599","DOI":"10.5530\/ijper.56.3s.168","volume":"56","author":"K Susmitha","year":"2022","unstructured":"Susmitha K, Menaka M. LC-ESI-MS\/MS method for the Fosamprenavir quantification bioanalytical method development and validation for the quantification Fosamprenavir in human plasma by LC-ESI-MS\/MS. Indian J Pharm Educ Res. 2022;56:S599\u2013604.","journal-title":"Indian J Pharm Educ Res"},{"key":"892_CR22","doi-asserted-by":"crossref","unstructured":"Singh GVS, Reddy DRS, Divakar TE. (2019) Stable liquid chromatography method for the resolution and quantification of related impurities of Fosamprenavir in bulk and pharmaceutical formulations. Indian Drugs 56(9).","DOI":"10.53879\/id.56.09.11896"},{"key":"892_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11094-022-02610-5","volume":"56","author":"SK Ettaboina","year":"2022","unstructured":"Ettaboina SK, Katakam LN, Dongala T. Development and validation of a stability-indicating RP-HPLC method for the determination of erythromycin-related impurities in topical dosage form. Pharm Chem J. 2022;56:131\u20137.","journal-title":"Pharm Chem J"},{"key":"892_CR24","doi-asserted-by":"crossref","unstructured":"Ettaboina SK, Nakkala K, Chathalingath N. (2022) Development and validation of rapid RP-HPLC method for determination of deferasirox in bulk and tablet dosage forms. Asian Journal of Pharmaceutical Analysis. 2022: 73\u2013\u20097.","DOI":"10.52711\/2231-5675.2022.00013"},{"key":"892_CR25","unstructured":"ICH, Quality Guidelines ICH. accessed January 18,. https:\/\/www.ich.org\/page\/quality-guidelines (2024)."},{"key":"892_CR26","unstructured":"Ettaboina SK, Nakkala K. (2021). Development and validation of new analytical methods for the simultaneous estimation of levamisole and Albendazole in bulk and tablet dosage form by RP-HPLC. Journal of Pharmaceutical Analytics and Insights. 2021:1\u20136."}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00892-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:27:48Z","timestamp":1741951668000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00892-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["892"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00892-5","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}